Brind.
  1. FDA is adjusting drug review strategies, showing openness to less data, while China surpasses the U.S. in drug research.

An experimental drug, sourced from China, is under FDA scrutiny after marketing claims of being 'the ultimate good' and subsequent warnings were issued.

3 reports, 3 independent Updated Aug 1
Gone quiet
Reports
3
Developments
2
Repetition
33%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 3 independent outlets

An experimental drug, sourced from China, is under FDA scrutiny after marketing claims of being 'the ultimate good' and subsequent warnings were issued.

Who's involved

What this event is mainly about
Eli Lilly and CompanyFDAChina

How it developed

Newest first. Tap a step to see who reported it.
  1. Eli Lilly faces competitive pressure from Chinese labs, linked to Cambridge research.1 source
  2. FDA issued warnings regarding the marketing and sales of a drug sourced from China.1 source

Keep exploring

Part of

FDA is adjusting drug review strategies, showing openness to less data, while China surpasses the U.S. in drug research. All 2 developments

The entities involved

Related events

Coverage

Newest first; wire copies grouped